Analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
GLMD opened at $0.39 on Thursday. The business’s fifty day moving average is $0.36 and its two-hundred day moving average is $0.38. The company has a market cap of $1.95 million, a price-to-earnings ratio of -0.12 and a beta of 0.87. Galmed Pharmaceuticals has a one year low of $0.26 and a one year high of $7.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its quarterly earnings data on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- What Are the U.K. Market Holidays? How to Invest and Trade
- AMD is Down 35%. Now is the Time to Buy the Dip
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Amazon Stands Tall: New Highs Are in Sight
- Learn Technical Analysis Skills to Master the Stock Market
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
